Corcept Therapeutics (CORT) Cash from Financing Activities (2010 - 2026)

Corcept Therapeutics has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $760000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $760000.0, up 101.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$179.8 million (down 165.95% YoY), and the FY2025 annual result was -$220.4 million, down 677.33% from the prior year.
• Cash from Financing Activities came in at $760000.0 for Q1 2026 at Corcept Therapeutics, up from -$31.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $766000.0 in Q4 2023 to a low of -$145.8 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is -$3.9 million (2023), against an average of -$24.4 million.
• Across the five-year window, Cash from Financing Activities surged 1355.74% in 2023 and plunged 7230.2% in 2025, its largest moves.
• Corcept Therapeutics' Cash from Financing Activities stood at -$61000.0 in 2022, then soared by 1355.74% to $766000.0 in 2023, then plunged by 695.82% to -$4.6 million in 2024, then slumped by 583.96% to -$31.2 million in 2025, then surged by 102.43% to $760000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $760000.0 (Q1 2026), -$31.2 million (Q4 2025), and -$46.4 million (Q3 2025), per Business Quant data.